2015 Q1 Form 10-K Financial Statement
#000114420415020124 Filed on March 31, 2015
Income Statement
| Concept | 2015 Q1 | 2014 | 2013 Q4 |
|---|---|---|---|
| Revenue | $723.1K | $4.123M | $880.0K |
| YoY Change | -31.92% | 70.18% | 46.67% |
| Cost Of Revenue | $304.5K | $2.134M | $840.0K |
| YoY Change | -54.04% | 11.63% | 1300.0% |
| Gross Profit | $418.6K | $1.989M | $40.00K |
| YoY Change | 4.74% | 289.15% | -92.73% |
| Gross Profit Margin | 57.89% | 48.24% | 4.55% |
| Selling, General & Admin | $1.515M | $5.553M | $1.010M |
| YoY Change | 40.23% | 115.51% | 48.53% |
| % of Gross Profit | 361.97% | 279.2% | 2525.0% |
| Research & Development | $951.0K | $2.432M | $30.00K |
| YoY Change | 301.66% | 39.84% | -95.59% |
| % of Gross Profit | 227.2% | 122.26% | 75.0% |
| Depreciation & Amortization | $20.00K | $48.43K | $10.00K |
| YoY Change | 0.0% | 21.4% | -50.0% |
| % of Gross Profit | 4.78% | 2.43% | 25.0% |
| Operating Expenses | $2.682M | $8.882M | $1.040M |
| YoY Change | 72.59% | 70.01% | -23.53% |
| Operating Profit | -$2.712M | -$6.893M | -$1.000M |
| YoY Change | 134.94% | 46.24% | 23.46% |
| Interest Expense | $2.613K | -$310.0K | -$120.0K |
| YoY Change | -101.91% | -26.68% | 0.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$2.454M | -$2.814M | |
| YoY Change | -1470.0% | 565.61% | |
| Pretax Income | -$4.717M | -$6.482M | -$1.130M |
| YoY Change | 383.75% | 26.2% | 21.51% |
| Income Tax | $0.00 | -$385.6K | -$460.0K |
| % Of Pretax Income | |||
| Net Earnings | -$4.717M | -$9.322M | -$670.0K |
| YoY Change | 383.75% | 99.27% | 24.07% |
| Net Earnings / Revenue | -652.35% | -226.1% | -76.14% |
| Basic Earnings Per Share | -$0.19 | ||
| Diluted Earnings Per Share | -$0.19 | -$648.1K | -$67.88K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 24.64M shares | 245.1M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2015 Q1 | 2014 | 2013 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $13.40M | $5.550M | $2.200M |
| YoY Change | 19.64% | 154.59% | 29.41% |
| Cash & Equivalents | $10.42M | $3.610M | $2.183M |
| Short-Term Investments | $2.900M | $1.940M | |
| Other Short-Term Assets | $100.0K | $700.0K | $600.0K |
| YoY Change | -50.0% | 14.75% | 20.0% |
| Inventory | $702.9K | $540.0K | $245.6K |
| Prepaid Expenses | |||
| Receivables | $700.0K | $820.0K | $500.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $14.88M | $7.610M | $3.487M |
| YoY Change | 25.82% | 118.05% | 18.62% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $330.3K | $250.0K | $144.4K |
| YoY Change | 112.55% | 78.57% | -0.83% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $652.2K | $60.00K | $414.4K |
| YoY Change | 59.2% | 20.0% | 63.0% |
| Total Long-Term Assets | $982.5K | $860.0K | $558.8K |
| YoY Change | 73.87% | 53.57% | 39.75% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $14.88M | $7.610M | $3.487M |
| Total Long-Term Assets | $982.5K | $860.0K | $558.8K |
| Total Assets | $15.86M | $8.470M | $4.046M |
| YoY Change | 28.01% | 109.14% | 21.15% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $475.2K | $700.0K | $786.5K |
| YoY Change | -9.94% | -11.39% | -1.77% |
| Accrued Expenses | $700.0K | $820.0K | $400.0K |
| YoY Change | 75.0% | 127.78% | 33.33% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $1.600M | |
| YoY Change | -100.0% | 77.78% | |
| Total Short-Term Liabilities | $6.198M | $4.510M | $3.065M |
| YoY Change | 87.91% | 47.39% | 47.58% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $6.198M | $4.510M | $3.065M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $6.200M | $4.510M | $3.065M |
| YoY Change | 87.88% | 47.39% | 47.58% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$129.1M | -$105.8M | |
| YoY Change | |||
| Common Stock | $24.68K | $10.05K | |
| YoY Change | -91.75% | -95.32% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $9.666M | $3.960M | -$14.27M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $15.86M | $8.470M | $4.046M |
| YoY Change | 28.01% | 109.14% | 21.15% |
Cashflow Statement
| Concept | 2015 Q1 | 2014 | 2013 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$4.717M | -$9.322M | -$670.0K |
| YoY Change | 383.75% | 99.27% | 24.07% |
| Depreciation, Depletion And Amortization | $20.00K | $48.43K | $10.00K |
| YoY Change | 0.0% | 21.4% | -50.0% |
| Cash From Operating Activities | -$2.409M | -$6.661M | -$1.100M |
| YoY Change | 201.08% | 90.9% | 42.86% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $104.0K | $153.2K | -$170.0K |
| YoY Change | 386.69% | 295.92% | 750.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$990.0K | -$1.940M | |
| YoY Change | -79.16% | ||
| Cash From Investing Activities | -$1.135M | -$2.312M | -$170.0K |
| YoY Change | -76.22% | 968.55% | 750.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $9.409M | ||
| YoY Change | -0.44% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $10.01M | $10.02M | 1.180M |
| YoY Change | 2.13% | 138.35% | 156.52% |
| NET CHANGE | |||
| Cash From Operating Activities | -$2.409M | -$6.661M | -1.100M |
| Cash From Investing Activities | -$1.135M | -$2.312M | -170.0K |
| Cash From Financing Activities | $10.01M | $10.02M | 1.180M |
| Net Change In Cash | $6.468M | $1.044M | -90.00K |
| YoY Change | 52.83% | 110.02% | -72.73% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$2.409M | -$6.661M | -$1.100M |
| Capital Expenditures | $104.0K | $153.2K | -$170.0K |
| Free Cash Flow | -$2.513M | -$6.814M | -$930.0K |
| YoY Change | 205.91% | 93.15% | 24.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b><font>1</font>. BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents Medical Inc., its wholly-owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the “European Subsidiary”), collectively referred to as “the Company.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font: 10pt Times New Roman, Times, Serif;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company believes that it has adequate funding for more than the next twelve months of operations, however, it may have to raise additional capital to fund its future operations.</font></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font: 10pt Times New Roman, Times, Serif;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"></font></font><br/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font: 10pt Times New Roman, Times, Serif;"><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">As of December 31, 2014, the Company had an accumulated deficit of $<font>124,394,120</font>, which included net losses of $<font>9,321,672</font> for the year ended December 31, 2014 and $<font>4,677,795</font> for the year ended December 31, 2013. Our losses have resulted principally from costs incurred in the research and development of our polymer technology and selling, general and administrative expenses. We intend to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, we will achieve profitability are uncertain. Our ability to achieve profitability will depend, among other things, on successfully completing the development of our technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE Mark and for potential label extensions of our current CE Mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance our activities. No assurance can be given that our product development efforts will be successful, that our current CE Mark will enable us to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of our products will be manufactured at a competitive cost and will be of acceptable quality, or that the we will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</font></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"> </p> </div> | |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
144393 | USD |
| CY2014 | us-gaap |
Depreciation
Depreciation
|
48429 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
39891 | USD |
| CY2014Q4 | us-gaap |
Other Intangible Assets Net
OtherIntangibleAssetsNet
|
557528 | USD |
| CY2013Q4 | us-gaap |
Other Intangible Assets Net
OtherIntangibleAssetsNet
|
360481 | USD |
| CY2014Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
58270 | USD |
| CY2013Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
53894 | USD |
| CY2014Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
615798 | USD |
| CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
414375 | USD |
| CY2014 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends, valuation methods used to determine the fair value of the warrant liability and valuation methods used in determining any debt discount associated with the convertible securities.</p> </div> | |
| CY2014 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>Concentration of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">As of December 31, 2014, <font>three</font> distributors accounted for approximately <font>53</font> percent of outstanding grant and accounts receivable. As of December 31, 2013, a U.S. Government agency accounted for approximately <font>66</font> percent of outstanding accounts receivable. For the year ended December 31, 2014, approximately <font>24</font> percent of revenue was from <font>two</font> U.S. government grant agencies and approximately <font>12</font> percent of revenues was from <font>one</font> distributor. For the year ended December 31, 2013, approximately <font>62</font> percent of revenues were from <font>two</font> U.S. government agencies. For the year ended December 31, 2013, no other agency, distributor, or direct customer represented more than 10% of the Company's revenue.</p> </div> | |
| CY2014 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>Reclassifications</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Certain reclassifications have been made to the December 31, 2013 financial statements in order to conform to the 2014 financial statement presentation. There was no change in the reported amount of the accumulated deficit as a result of these reclassifications.</p> </div> | |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2702457 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2545747 | USD |
| CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2456636 | USD |
| CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2401354 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
245821 | USD |
| CY2014 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
17118 | USD |
| CY2013 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
24459 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
26500 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
26500 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
21000 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
14100 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
14000 | USD |
| CY2014Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
293758 | USD |
| CY2013Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
80880 | USD |
| CY2014Q4 | ctso |
Accrued Travel And Entertainment Expence Current
AccruedTravelAndEntertainmentExpenceCurrent
|
107542 | USD |
| CY2013Q4 | ctso |
Accrued Travel And Entertainment Expence Current
AccruedTravelAndEntertainmentExpenceCurrent
|
USD | |
| CY2014Q4 | ctso |
Clinical Study Costs Payable Current
ClinicalStudyCostsPayableCurrent
|
36465 | USD |
| CY2013Q4 | ctso |
Clinical Study Costs Payable Current
ClinicalStudyCostsPayableCurrent
|
15016 | USD |
| CY2014Q4 | ctso |
Sales Payroll And Income Taxes Payable Current
SalesPayrollAndIncomeTaxesPayableCurrent
|
64745 | USD |
| CY2013Q4 | ctso |
Sales Payroll And Income Taxes Payable Current
SalesPayrollAndIncomeTaxesPayableCurrent
|
179970 | USD |
| CY2014Q4 | ctso |
Accrued Salaries And Commissions Current
AccruedSalariesAndCommissionsCurrent
|
204515 | USD |
| CY2013Q4 | ctso |
Accrued Salaries And Commissions Current
AccruedSalariesAndCommissionsCurrent
|
USD | |
| CY2014Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
45200 | USD |
| CY2013Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
15000 | USD |
| CY2014Q4 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
30000 | USD |
| CY2013Q4 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
USD | |
| CY2014Q4 | ctso |
Accrued Director Fees Current
AccruedDirectorFeesCurrent
|
11250 | USD |
| CY2013Q4 | ctso |
Accrued Director Fees Current
AccruedDirectorFeesCurrent
|
USD | |
| CY2014Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
USD | |
| CY2013Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
25326 | USD |
| CY2014Q4 | ctso |
Accrued Financing Costs Current
AccruedFinancingCostsCurrent
|
USD | |
| CY2013Q4 | ctso |
Accrued Financing Costs Current
AccruedFinancingCostsCurrent
|
36371 | USD |
| CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
31409 | USD |
| CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9137 | USD |
| CY2014Q4 | ctso |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
824884 | USD |
| CY2013Q4 | ctso |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
361700 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
1.00 | pure |
| CY2014 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
10500 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.20 | pure |
| CY2014 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.05 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.009 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.340 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.298 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
|
pure | |
| CY2014 | ctso |
Proceeds From Sale Of Net Operating Loss Carryforwards
ProceedsFromSaleOfNetOperatingLossCarryforwards
|
386000 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
-7700000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
-3300000 | USD |
| CY2013 | ctso |
Proceeds From Sale Of Net Operating Loss Carryforwards
ProceedsFromSaleOfNetOperatingLossCarryforwards
|
458000 | USD |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.34 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.34 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
0.010 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
0.029 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.010 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
|
0.004 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
pure | |
| CY2013 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
pure | |
| CY2014Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
816000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
7.8125 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.283 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0143 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y2M8D | |
| CY2014Q4 | us-gaap |
Share Price
SharePrice
|
10.22 | |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
816000 | shares |
| CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
7.8125 | |
| CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.283 | pure |
| CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0162 | pure |
| CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
| CY2014Q1 | us-gaap |
Share Price
SharePrice
|
6.00 | |
| CY2014 | ctso |
Fair Value Warranty Liability Upon Issuance
FairValueWarrantyLiabilityUponIssuance
|
862920 | USD |
| CY2014 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
2118498 | USD |
| CY2014Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
211240 | USD |
| CY2014Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Rolling Year Three
OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree
|
98445 | USD |
| CY2014 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
328000 | USD |
| CY2013 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
315000 | USD |
| CY2014Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
309685 | USD |
| CY2013Q2 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
1098000 | USD |
| CY2013Q2 | ctso |
Debt Instrument Maturity Period
DebtInstrumentMaturityPeriod
|
P1Y | |
| CY2013Q2 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.08 | pure |
| CY2013Q2 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
3.125 | |
| CY2013Q2 | ctso |
Debt Instrument Percent Of Principal Amount
DebtInstrumentPercentOfPrincipalAmount
|
0.50 | pure |
| CY2013Q2 | ctso |
Warrant Exercise Price
WarrantExercisePrice
|
3.75 | |
| CY2013Q2 | us-gaap |
Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
|
379469 | shares |
| CY2013Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
745000 | USD |
| CY2013Q3 | ctso |
Debt Instrument Maturity Period
DebtInstrumentMaturityPeriod
|
P1Y | |
| CY2013Q3 | ctso |
Warrant Exercise Price
WarrantExercisePrice
|
2.50 | |
| CY2013Q3 | ctso |
Debt Instrument Percent Of Principal Amount
DebtInstrumentPercentOfPrincipalAmount
|
0.50 | pure |
| CY2013Q3 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
3.125 | |
| CY2013Q3 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.08 | pure |
| CY2013 | us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
1843000 | USD |
| CY2013Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
1511883 | USD |
| CY2013Q4 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
171012 | USD |
| CY2013 | us-gaap |
Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
|
160105 | USD |
| CY2014 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
199000 | USD |
| CY2013 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
311000 | USD |
| CY2014 | us-gaap |
Freight Costs
FreightCosts
|
103000 | USD |
| CY2013 | us-gaap |
Freight Costs
FreightCosts
|
33000 | USD |
| CY2014Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
142693 | USD |
| CY2013Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
107098 | USD |
| CY2014Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
326047 | USD |
| CY2013Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
100528 | USD |
| CY2014Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
68826 | USD |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2183030 | USD |
| CY2013Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
37982 | USD |
| CY2014 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2014 | us-gaap |
Advertising Expense
AdvertisingExpense
|
142000 | USD |
| CY2013 | us-gaap |
Advertising Expense
AdvertisingExpense
|
269000 | USD |
| CY2014 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
386000 | USD |
| CY2013 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
14000 | USD |
| CY2014Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
3756 | USD |
| CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
| CY2014Q4 | ctso |
Number Of Countries In Which Product Marketed
NumberOfCountriesInWhichProductMarketed
|
29 | item |
| CY2014Q4 | ctso |
Number Of Patents Issued
NumberOfPatentsIssued
|
32 | item |
| CY2014Q4 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
25 | pure |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-11625145 | USD |
| CY2014 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2014 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-12-31 | |
| CY2014 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2014 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2014 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2014Q2 | dei |
Entity Public Float
EntityPublicFloat
|
72139000 | USD |
| CY2014 | dei |
Entity Registrant Name
EntityRegistrantName
|
Cytosorbents Corp | |
| CY2014 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001175151 | |
| CY2015Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
24637822 | shares |
| CY2014 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014 | dei |
Document Type
DocumentType
|
10-K | |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
456937 | USD |
| CY2013 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
USD | |
| CY2013 | ctso |
Dividends Preferred Stock Series B
DividendsPreferredStockSeriesB
|
-2378919 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
65468 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
20386 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2299967 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
100000 | USD |
| CY2013 | ctso |
Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
|
1226042 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
331117 | USD |
| CY2013 | ctso |
Stock Issued During Period Value Stock Cash Warrants Exercised
StockIssuedDuringPeriodValueStockCashWarrantsExercised
|
139526 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
20194 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-43325 | USD |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4677795 | USD |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3605280 | USD |
| CY2014Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
1944547 | USD |
| CY2013Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
USD | |
| CY2014Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
819151 | USD |
| CY2013Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
453017 | USD |
| CY2014Q4 | us-gaap |
Inventory Net
InventoryNet
|
537566 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
245608 | USD |
| CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
700462 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
605312 | USD |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
7607006 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
3486967 | USD |
| CY2014Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
861619 | USD |
| CY2013Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
558768 | USD |
| CY2014Q4 | us-gaap |
Assets
Assets
|
8468625 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
4045735 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
698307 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
786517 | USD |
| CY2014Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
833 | USD |
| CY2013Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
272359 | USD |
| CY2014Q4 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
2981418 | USD |
| CY2013Q4 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
USD | |
| CY2014Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
USD | |
| CY2013Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
1644356 | USD |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4505442 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3064932 | USD |
| CY2014Q4 | ctso |
Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
|
USD | |
| CY2013Q4 | ctso |
Preferred Stock Value Not Included In Stockholders Equity
PreferredStockValueNotIncludedInStockholdersEquity
|
15246350 | USD |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
23305 | USD |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
10053 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
128106297 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
91584402 | USD |
| CY2014Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
227701 | USD |
| CY2013Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-55987 | USD |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-124394120 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-105805775 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3963183 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-14265547 | USD |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
8468625 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
4045735 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
695841 | USD |
| CY2014 | us-gaap |
Dividends Preferred Stock
DividendsPreferredStock
|
USD | |
| CY2014 | ctso |
Dividends Preferred Stock Series B
DividendsPreferredStockSeriesB
|
-9028360 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
180100 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
24274708 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
300000 | USD |
| CY2013Q4 | ctso |
Convertible Notes Current Unamortized Discount
ConvertibleNotesCurrentUnamortizedDiscount
|
198644 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
748545 | USD |
| CY2014 | ctso |
Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
|
1990440 | USD |
| CY2014 | ctso |
Stock Issued During Period Value Stock Cash Warrants Exercised
StockIssuedDuringPeriodValueStockCashWarrantsExercised
|
156250 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
109200 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
283688 | USD |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9321672 | USD |
| CY2014 | ctso |
Stock Issued During Period Value Offering
StockIssuedDuringPeriodValueOffering
|
10200000 | USD |
| CY2014 | ctso |
Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
|
USD | |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
10052782 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23304640 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23304640 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
10052782 | shares |
| CY2014 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
3135387 | USD |
| CY2013 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
821787 | USD |
| CY2014 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
978271 | USD |
| CY2013 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
1600880 | USD |
| CY2014 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
9167 | USD |
| CY2013 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
USD | |
| CY2014 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
4122825 | USD |
| CY2013 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
2422667 | USD |
| CY2014 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
2133888 | USD |
| CY2013 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
1911565 | USD |
| CY2014 | us-gaap |
Gross Profit
GrossProfit
|
1988937 | USD |
| CY2013 | us-gaap |
Gross Profit
GrossProfit
|
511102 | USD |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2431759 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1738938 | USD |
| CY2014 | us-gaap |
Professional Fees
ProfessionalFees
|
1284947 | USD |
| CY2013 | us-gaap |
Professional Fees
ProfessionalFees
|
908644 | USD |
| CY2014 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
5551023 | USD |
| CY2013 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
2576751 | USD |
| CY2014 | us-gaap |
Operating Expenses
OperatingExpenses
|
9267729 | USD |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
5224333 | USD |
| CY2014 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7278792 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4713231 | USD |
| CY2014 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-310024 | USD |
| CY2013 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-422843 | USD |
| CY2013 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
USD | |
| CY2014 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2428522 | USD |
| CY2013 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-422843 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-9707314 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-5136074 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-385642 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-458279 | USD |
| CY2014 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
9266673 | USD |
| CY2013 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
2395520 | USD |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-18588345 | USD |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7073315 | USD |
| CY2014 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.29 | |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.75 | |
| CY2014 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
14382813 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
9440763 | shares |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
283688 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-43325 | USD |
| CY2014 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9037984 | USD |
| CY2013 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-4721120 | USD |
| CY2014 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
180100 | USD |
| CY2013 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
65468 | USD |
| CY2014 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
65547 | USD |
| CY2013 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
64350 | USD |
| CY2014 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
198644 | USD |
| CY2013 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
311248 | USD |
| CY2014 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
4106 | USD |
| CY2013 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
USD | |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
695841 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
456937 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
412118 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
401238 | USD |
| CY2014 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
303129 | USD |
| CY2013 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-436764 | USD |
| CY2014 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
108153 | USD |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
129219 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
4784 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
6942 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
497453 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
118748 | USD |
| CY2014 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-271526 | USD |
| CY2013 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
272359 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6661193 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3489320 | USD |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
153157 | USD |
| CY2013 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
USD | |
| CY2014 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
6689547 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
38684 | USD |
| CY2014 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
214165 | USD |
| CY2013 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
177672 | USD |
| CY2014 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
4745000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
USD | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2311869 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-216356 | USD |
| CY2014 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
9751455 | USD |
| CY2013 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
2199967 | USD |
| CY2014 | us-gaap |
Proceeds From Other Debt
ProceedsFromOtherDebt
|
USD | |
| CY2014 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
109201 | USD |
| CY2013 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
20194 | USD |
| CY2014 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
156250 | USD |
| CY2013 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
139526 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
10016906 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4202687 | USD |
| CY2014 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
378406 | USD |
| CY2013 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-43325 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1422250 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
453686 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1729344 | USD |
| CY2014 | us-gaap |
Interest Paid
InterestPaid
|
USD | |
| CY2013 | us-gaap |
Interest Paid
InterestPaid
|
USD | |
| CY2013 | ctso |
Fair Value Warranty Liability Upon Issuance
FairValueWarrantyLiabilityUponIssuance
|
USD | |
| CY2014 | ctso |
Debt Discount
DebtDiscount
|
USD | |
| CY2013 | ctso |
Debt Discount
DebtDiscount
|
331117 | USD |
| CY2014 | us-gaap |
Stock Issued1
StockIssued1
|
7137 | USD |
| CY2013 | us-gaap |
Stock Issued1
StockIssued1
|
49647 | USD |
| CY2014 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
1990440 | USD |
| CY2013 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
1226042 | USD |
| CY2014 | ctso |
Supplemental Noncash Transactions
SupplementalNoncashTransactions
|
748545 | USD |
| CY2013 | ctso |
Supplemental Noncash Transactions
SupplementalNoncashTransactions
|
USD | |
| CY2014 | ctso |
Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
|
9266673 | USD |
| CY2013 | ctso |
Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
|
2395520 | USD |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2014Q1 | ctso |
Subscription Agreement Offering Units
SubscriptionAgreementOfferingUnits
|
1632000 | shares |
| CY2014Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
10200000 | USD |
| CY2014Q1 | us-gaap |
Share Price
SharePrice
|
6.25 | |
| CY2014Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
92712.27 | shares |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
816000 | shares |
| CY2014Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9451000 | USD |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
695800 | USD |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
456900 | USD |
| CY2014Q1 | ctso |
Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
|
2762500 | USD |
| CY2014Q1 | ctso |
Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
|
16575000 | USD |
| CY2014Q1 | ctso |
Cash Placement Agent Fee As Percentage Of Gross Proceeds Of Sale Of Units
CashPlacementAgentFeeAsPercentageOfGrossProceedsOfSaleOfUnits
|
0.06 | pure |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
0.50 | shares |
| CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
7.8125 | |
| CY2014Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
| CY2014Q1 | ctso |
Out Of Pocket Expenses As Percentage Of Gross Proceeds
OutOfPocketExpensesAsPercentageOfGrossProceeds
|
0.02 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0093 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0206 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.48 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.75 | |
| CY2014 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.88 | |
| CY2014 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
539.25 | |
| CY2014Q4 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableAggregateIntrinsicValue
|
10001000 | USD |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1427657 | shares |
| CY2014Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
5.80 | |
| CY2014Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
389000 | USD |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsVestedNumber
|
548000 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
|
624000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1466709 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.75 | |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y1M6D | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
563040 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
2.75 | |
| CY2013 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
|
P5Y6M | |
| CY2013 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
|
89400 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
3.00 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
1129 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
192.75 | |
| CY2013 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
22269 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.00 | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1916951 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.00 | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y1M6D | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
732800 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
5.02 | |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
|
P8Y8M12D | |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
|
227810 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
3.26 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
2502 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
45.80 | |
| CY2014 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
117252 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.97 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2302187 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.37 | |
| CY2014Q4 | ctso |
Agreement To Purchase Shares Value
AgreementToPurchaseSharesValue
|
8500000 | USD |
| CY2014 | ctso |
Period In Which Common Stock Can Be Sold
PeriodInWhichCommonStockCanBeSold
|
P32M | |
| CY2013Q4 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
|
536720 | shares |
| CY2013Q4 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
|
0.85 | |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriod
|
732800 | shares |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Granted In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantedInPeriodWeightedAverageGrantDateFairValue
|
1.47 | |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeituresInPeriod
|
194450 | shares |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
|
0.83 | |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriod
|
200540 | shares |
| CY2014 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
1.91 | |
| CY2014Q4 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber
|
874530 | shares |
| CY2014Q4 | ctso |
Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue
|
1.37 | |
| CY2014Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1613160 | shares |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y1M6D | |
| CY2014 | dei |
Trading Symbol
TradingSymbol
|
ctso |
